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Abstract (English) 
 
Introduction 
Endoscopic ultrasound (EUS) elastography is a recent ultrasound method used for 
the real-time visualization and evaluation of tissue elasticity. Qualitative and 
quantitative methods have been used, in particular in evaluation of pancreatic 
diseases and malignant lymph nodes, with interesting results regarding the 
accuracy and the differential diagnosis between malignant and benign masses.  No 
consensus has been reached with regard to the superiority of different quantitative 
methods, but strain ratio and strain histogram (SH) remain the most used. SH 
corresponds to a graphical representation of the color distribution in a region of 
interest (ROI), and mean SH (mSH) value is a SH-derived quantitative measure 
of the global hardness in the evaluated ROI. 
 
Materials and methods 
The aim of the present study was to describe the different elastographic patterns 
of solid pancreatic masses (pancreatic adenocarcinoma, PA, and pancreatic 
neuroendocrine tumor, pNET) using the mSH value. A group of normal patients 
was enrolled to define the normal pancreatic elasticity. 
This is a prospective, observational, monocentric study.  
Experienced EUS examiners performed the endoscopic procedure and 
elastographic measures. Contrast enhancement was performed, and according to 
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the European Federation Societies of Ultrasound in Medicine and Biology 
guidelines and recommendations, 2 phases were defined for CE-US and CEH-
EUS of the pancreas: an early and/or arterial phase (starting from 10 to 30 
seconds) and a late and/or venous phase (from 30 to 120 seconds). Enhancement 
was evaluated in arterial phase. When the lesion resulted hypovascular (hypo-
enhanced), the aspect was defined as typical for adenocarcinoma while an 
hypervascular lesion (with strong arterial hyper-enhancement) was considered 
typical of neuroendocrine tumors.  
SH was calculated automatically by machine integrated software in a ROI 
manually selected by the operator. Four parameters were calculated using the 
histogram to quantify the elasticity of the pancreas: the mSH, the standard 
deviation of the histogram, the kurtosis and the skewness. Three different 
measures were performed by the same operator and the mean value of the previous 
described values was evaluated. After the elastographic measure a FNA was 
performed when a lesion was observed. We used the histology obtained by FNA 
or surgical specimens or the global assessment of cytology and imaging as 
reference standard for the diagnosis, except in case of normal examinations.  
 
Results 
A total of 88 patients were included: 9 normals, 45 PA, 9 pNET (5 grade 1, 4 
grade2-3), 5 chronic pancreatitis, 20 others (IPMN, metastatic lesions, pancreatic 
cystoadenoma, etc).  Only patients with normal pancreas, PA and pNET were 
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included in the statistical analysis. Mean age was 64 (range: 19-88). All the 
patients presenting a pancreatic lesion, except one, received the contrast. All the 
patients with pNET presented a typical hypervascular enhancement. On the other 
hand, of patients with histological proven pancreatic adenocarcinoma, only 37 
presented a typical hypoenhancement, while 5 presented an hypervascularisation 
and 2 patients an atypical enhancement (represented by a partial arterial 
enhancement). Regarding elastography, we obtained a statistically significant 
difference between the malignant lesions (p-Net grade 2/3 and adenocarcinoma) 
and normal pancreas, considering all the parameters evaluated (mSH, standard 
deviation, kurtosis and skewness).  No differences were found in elastographic 
measurement between p-NET and adenocarcinoma, neither between p-NET grade 
1 (that, considering the good prognosis and slow evolution, could be considered 
neither as benign neither as malign) and p-NET grade 2/3. At univariate analysis 
we found that all the elastographic parameters measured were capable to 
differentiate benign versus malign disease, with a cut-off calculated with ROC-
curves of 43.250 for mSH, 44.63 for standard deviation, 1.5 for the skewness and 
5 for kurtosis. At multivariate analysis only mSH resulted statistically 
significative to distinguish benign versus malign lesions. At a model constructed 
by logistic regression (9.8958 – 0.3170*moyenne + 0.2989*SD + 0.7935*kurtosis 
– 7.0642*skewness) a cut off of 0.57 was found to distinguish benign versus 
malign lesions. 
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Conclusions 
Mean strain histogram seems able to differentiate pancreatic cancer from benign 
pancreas. EUS elastography could potentially be used in negative EUS–FNA 
cases, which represent up to 25% of patients with focal masses. The presence of 
a strong suspicion of pancreatic cancer is indicated when combining meanSH, 
standard deviation, skewness and kurtosis in a statistical model we obtain a cut-
off>0.57. 
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Abstract (Italian) 
 
Introduzione 
L’elastometria condotta tramite ecoendoscopia è una nuova tecnica utilizzata per 
la visualizzazione e la valutazione in real time dell’elasticità dei tessuti. È noto 
infatti che i tessuti patologici, quali ad esempio i tessuti tumorali, presentano 
un’elasticità diversa rispetto ai tessuti normali. Fino ad oggi sono state utilizzate 
tecniche di misurazione dell’elasticità sia di tipo qualitativo che di tipo 
quantitativo. Le misure qualitative sono però gravate da una scarsa riproducibilità. 
Per tale ragione esse sono state praticamente abbandonate afavore di misure 
quantitative. Non esiste un consenso circa la superiorità di un metodo quantitativo 
rispetto ad un altro, ma lo “strain ratio” (SR) e lo “strain histogram” restano le 
metodiche più utilizzate. Lo SH, utilizzato in questo studio, corrisponde a una 
rappresentazione grafica della distribuzione del colore in una determinata area di 
interesse, e il valore del mSH è una misura dell’elasticità globale in un’area di 
interesse prescelta, normalmente corrispondente alla lesione. L’accuratezza 
dell’elastometria è stata valutata nelle patologie pancreatiche e linfonodali, 
mostrando risulatati interessanti soprattutto nella diagnosi differenziale tra le 
masse benigne e le masse maligne. 
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Materiali e metodi 
Lo scopo del nostro studio è la quantificazione del pattern elastografico nel 
pancreas normale, nell’adenocarcinoma pancreatico (AP) e nei tumori 
neuroendocrine (NET). Si tratta di uno studio prospettico, monocentrico e 
osservazionale. L’ecoendoscopia con contrasto è stata effettuata e, secondo le line 
guida della società Europea di ecografia, sono state individuate 2 fasi 
contrastografiche per lo studio del pancreas: la prima, dai 10 ai 30 secondi, 
denominata fase precoce o arteriosa e la seconda, tardiva o venosa, dai 30 ai 120 
secondi. L’enhancement delle lesioni pancreatiche è stato valutato in fase 
arteriosa. All’ecoendoscopia con contrasto, l’aspetto tipico di AP è definito in 
presenza di ipo-enhancement, mentre l’aspetto tipèico in caso di NET è definite 
in presenza di iper-enhancement arterioso. Successivamente all’elastometria è 
stata eseguita un’elastografia. Lo SH è stato calcolato automaticamente da un 
software in un’area scelta manualmente dall’operatore. 4 parametri sono stati 
presi in considerazione: lo SH medio (Msh), la deviazione standard, la kurtosis e 
lo swekness. 3 misure differenti sono state effettuate dallo stesso operatore e il 
valore medio delle  misure è stato preso in considerazione. Dopo la misura 
elastografica è stato eseguito il prelievo bioptico. Il risultato istologico ottenuto 
tramite biopsia è stato utilizzato come referenza per definire la natura della 
lesione, eccetto in caso di pancreas normale. 
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Risultati 
Nello studio sono stati inclusi 88 pazienti: 9 pancreas normali, 9 NET, 45 AP, 5 
pancreatiti croniche e 20 lesioni miste. Solo I pazienti con AP, NET e pancreas 
normale sono stati inclusi nell’analisi finale. Alla somministrazione di contrasto, 
i pazienti con NET hanno presentato un pattern ipervascolare dopo 
somministrazione di contrasto, mentre tra i pazienti con AP, solo 37 hanno 
presentato un pattern tipico ipovascolare, mentre 5 hanno presentato un pattern 
ipervascolare e 2 un enhancement atipico (arterioso parziale).  
Per ciò che riguarda l’elastografia, abbiamo ottenuto una differenza 
statisticamente significativa tra il pancreas normale e le lesioni maligne, per tutti 
i 4 parametri valutati (media, deviazione standard, kurtosis e skewness).  Invece, 
non abbiamo trovato una differenza statisticamente significativa tra i NET e l’AP. 
All’analisi univariata abbiamo trovato che tutti i parametri erano in grado di 
differenziare il pancreas benigno dal pancreas maligno, con un cut-off calcolato 
mediante la curva ROC di 43.250 per mSH, 44.63 per la deviazione standard, 1.5 
per lo skewness and 5 per la kurtosis. All’analisi multivariata, solo il mSH è 
risultato statisticamente significativo. Abbiamo costruito un modello statistico 
tramite regressione logistica (9.8958 – 0.3170*mSH + 0.2989*SD + 
0.7935*kurtosis – 7.0642*skewness), individuando un cut off di 0.57 per 
distinguere il pancreas normale dale lesioni maligne. 
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Conclusioni 
Il mSH sembra efficace nella differenziazione tra lesioni pancreatiche maligne e 
pancreas benigno. Proponiamo pertanto l’uso dell’elastometria, e del nostro 
modello statistico, per definire le lesioni da operare o da sorvegliare in caso di 
biopsia negativa. Riteniamo infatti che, pur in caso di biopsia negativa, un indice 
elastografico superiore a 0.57 sia indicativo di una lesione maligna e pertanto 
necessiti di una presa in carico chirurgica.  
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Introduction 
 
Differential diagnosis in focal pancreatic masses remains a main clinical problem 
in a high number of patients, even considering that pancreatic adenocarcinoma 
(PA) and neuroendocrine tumors (NET) present a different treatment and 
prognosis. 
The gold standard tool for the differential diagnosis between these two 
histologically different cancers is the endoscopic ultrasound fine-needle 
aspiration (EUS-FNA) that presents the higher sensitivity and specificity 
compared to other diagnostic tools.  
Unlikely, EUS-FNA is technically demanding, needs a prolonged learning curve 
and multiple punctures may be necessary to obtain a sufficient amount of tissue. 
Furthermore EUS-FNA can be associated to iatrogenic complications, such as 
acute iatrogenic pancreatitis, bleeding and infections. In addition, the sensitivity 
of cytology for malignancy is limited, and false-negative results are obtained in 
up to 20 % to 40 % of cases, requiring new techniques. 
The rational of using elastometry in differential pancreatic masses diagnosis is the 
fact that pathological processes can induce alteration in tissue stiffness and that 
different tissues can be distinguished on the basis of their specific consistency. 
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Background 
 
 Pancreatic adenocarcinoma and neuro endocrine tumors 
 
Pancreatic adenocarcinoma (PA) is the fourth most common cause of cancer 
related death among men and women in United States. The peak of incidence is 
between the seventh and eighth decade of life.  
The incidence of PA increased in USA in the decade between 1999 and 2008 and 
this is probably related to the increasing prevalence of obesity, life expectancy 
and others unknown factors. Unlikely, the PA related mortality remains stable.  
Up to now, the known risk factors of PA are cigarette smoking, increased body 
max index (BMI), increased consumption of red/processed meat, occupational 
exposure to chemicals, such as beta-naphthylamine ans benzidine, and increased 
alcohol assumption. The role of diabetes mellitus is still debated, such as the role 
of antidiabetic drugs. 
True familial PA is a rare entity, but a genetic predisposition is present in up to 5-
10% of patients. The genetic cause of familial predisposition is frequently 
unknown but some familial well known cancer syndromes are associated with an 
increased risk. Between these syndromes there are Peutz-Jeghers syndrome and 
Lynch syndrome, both characterized by a colon cancer predisposition. An 
increased PA incidence has been found even in patients with BRCA2 (breast 
cancer susceptibility gene-2) mutations. 
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The role of the PA screening remains to be defined, but a recent PA screening 
project has been conducted in 225 asymptomatic high-risk individuals, screened 
with computer tomography (CT), or magnetic resonance imaging (MRI) or 
endoscopic ultrasounds (EUS). When the results of the 3 screening modalities 
were compared, EUS detected abnormalities in 45% of patients, compared with 
33% and 11% for MRI and CT respectively (1). 
Ductal adenocarcinoma and its variants account for over 90% of pancreatic 
malignancies. Presenting symptoms are not specific: weight loss, jaundice, pain, 
nausea, dyspepsia. All patients for whom there is a clinical suspicion of pancreatic 
cancer should undergo initial evaluation by CT or MRI and eventually to EUS. 
The role of EUS is more evident in staging the disease, providing complementary 
information regarding the vessels involvement, the distinction between benign 
and malignant stenosis, the cystic pancreatic lesions and the periampullary 
masses.  
The biopsy is not required before surgery but it is required before neo-adjuvant 
therapy or exclusive medical therapy. The histological diagnosis is made by fine 
needle aspiration and/or biopsy by EUS or CT. EUS approach should be preferred 
because of better diagnosis, safety and lower complications. 
PA is usually staged and graded according to the TNM classification, based on 
primary tumor extension (T), regional lymph nodes involvement (N) and distal 
metastasis presence (M). TNM staging and stage grouping are shown in Table 1a 
and 1b. 
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The therapeutical approach depends on the tumor resectability status, as defined 
below in the Table 1c: 
 
 
 
1) Resectable disease: surgery 
2) Borderline resectable disease: chemotherapy (CTh) +/- surgery 
3) Locally advanced disease, unresectable: radiotheraphy (RTh)/RTh-
CTh. Sometimes a resection is possible after.  
4) Metastatic disease: CTh, according to the OMS status. 
Pancreatic neuroendocrine tumors (NET) origin from cells of the pancreatic 
endocrine system. They account for approximately 1% of pancreatic cancers by 
incidence and 10% by prevalence. The peak incidence of occurrence is between 
40 and 69 years, but a significant number of patients is diagnosed before 35 years.  
Most of these tumors (estimated between 40 and 91%) are nonfunctional. In case 
of functional tumors, up to 70% are insulinomas, 15% glucagonomas, 10% 
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gastrinomas and somatostatinomas. The remaining tumors (5%) are VIPomas, 
PPomas and CCKomas. 
The clinical symptoms depends on the secreted hormone. NET can occur in the 
context of Multiple Endocrine Neoplasia (MEN)-1 syndrome. In this case they 
are typically multiple and they require a different treatment from sporadic NET. 
The diagnosis relies on CT or MRI scan and eventually on biochemical evaluation 
(symptom-guided). Serum chromogranine A and and pancreatic polypeptide may 
be tested as clinically appropriate. Somatostatine scintigraphy (SRS) and EUS are 
appropriate too.  
The role of EUS in non-functional NET is particularly relevant for small tumors 
and EUS-FNAB has shown good results in confirming the diagnosis.  
In case of functional NET, the role of EUS varies according to the histology and 
to the presence of syndromes such as the MEN-1 or the Zollinger Ellison 
Syndrome (ZES).  
In case of ZES, EUS is indicated when cross CT-scan or MRI are negatives and 
surgery has been considered. In these cases, EUS is known to detect most 
pancreatic gastrinomas, while it misses up to 50% tumors in case of duodenal 
localization.  
In case of MEN-1, EUS is more sensitive than cross-sectional imaging studies 
(CT, MRI, US) for the detection of small non-functional pNET, especially in the 
pancreatic head/body region and to determine their size. Furthermore, the 
presence of multiple pancreatic tumors with EUS is very suspicious of MEN1. 
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However, EUS is not generally recommended at present in all MEN-1 patients, 
because routine surgical resection of small NET (<2 cm) is not recommended and 
the EUS criteria on when to operate these patients are not established. Some 
experts recommended pancreatic EUS in selected MEN1 patients, especially if 
they have ZES or small non-functional NET on other imaging studies and are 
being followed without surgery, in an attempt to detect small nonfunctional 
tumors and to follow their growth in order to offer earlier surgery. In case of 
insulinoma, EUS is positive in 70–95% of cases and is the imaging study of choice 
if the other non-invasive studies are negative. Furthermore, EUS can help to 
determine if tumor enucleation is possible because it can evaluate the distance 
between the tumor and the pancreatic duct.  
In case of more rare functional tumors, EUS is not universally recommended as a 
first-line procedure and it may be used in circumstances where CT, MRI and SRS-
SPECT are inconclusive, especially preoperatively; in patients with liver 
metastasis, EUS is rarely necessary while it may be helpful in patients with large 
or aggressive tumors to more clearly define the tumor involvement where surgery 
is considered. 
NET are staged and graded according to the same TNM classification as PA. The 
therapeutically approach depends more on the WHO 2010 classification, that 
distinguishes between well-differentiated and poorly differentiated NET, 
according to a grading scheme based on mitotic count or Ki67 index. 
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Low grade NET or G1 present with a mitotic count < 2 per 10 high-power fields 
(HPF) and/or < 2% Ki67 index, intermediate grade or G2 with a mitotic count 2–
20 per 10 HPF and/or 3–20% Ki67 index and high grade NET or G3 with a mitotic 
count >20 per 10 HPF and/or >20% Ki67 index. Low grade (G1) and intermediate 
grade (G2) are defined as well-differentiated NET while high grade (G3) as poorly 
differentiated neuroendocrine carcinoma (NEC). This classification should be 
used as a general guide. In fact it is recognized that occasionally a 
morphologically well differentiated NET may have a proliferation index by Ki67 
index which technically falls into the high grade category. Clinical judgement 
should be used in such discordant cases. In general, this discordance should not 
cause a reclassification of a well differentiated NET into a poorly differentiated 
NEC (https://www.nccn.org/). 
According to the French Oncological Digestive Guidelines 
(http://www.tncd.org/), the main factors associated to a bad prognosis are the low 
grade of differentiation, the high mitotic count and index and the metastatic 
disease. The disease treatment is different according to the disease grading and 
can be resumed as follows: 
G1/G2 well differentiated: 
1) Non-metastatic disease: 
 no NEM-1 associated: surgery. Except if lesion <2 cm in the head 
of pancreas, grade G1 and asymptomatic: follow up. 
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 NEM-1 associated: follow up. Except if lesion >2 cm and/or 
increasing in diameter, and/or if lympho-adenopathies are 
presents and/or if the disease is symptomatic (insulinoma, 
glucagonoma, VIPoma). 
2) Metastatic: 
 Primary and secondary lesions operable: surgery.  
 Primary and/or secondary lesions not operable: evaluate lesions 
progression, treat symptoms and discuss primary tumor resection.  
If non progressive disease: somatostatine analogs or follow 
up. 
If progressive disease: anti-tumoral treatment (chemo-therapy 
or immuno-therapy). 
G3 well differentiated: 
 If good performance status and asymptomatic patient: like G1/G2 
 If bad performance status/ symptomatic patient: like G3 scarcely 
differentiated 
G3 scarcely differentiated: 
1) Non-metastatic disease: 
 If complete resection is possible: surgery 
 If complete resection is not possible: medical therapy by chemo-
therapy +/- radio therapy 
2) Metastatic disease: Chemo-therapy in urgency  
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 Endoscopic Ultrasounds (EUS), contrast enhancement EUS (CE-EUS) 
and EUS-elastography  
 
The endosonographic structure of the pancreas is uniformly iso/hyper-
echoic compared to liver. The overall sensitivity and specificity of transabdominal 
ultrasonography (tUS) and its different modalities for the detection of pancreatic 
lesions is not yet established. In case of PA, the tUS typical finding corresponds 
to a hypoechoic lesion with badly defined margins, often with spiculas, with a 
tendency to alter the gland contour. At contrast enhancement tUS (CE-tUS), PA 
is characterized by hypo-enhancement. tUS can visualize NET lesions with a 
sensitivity of approximately 30–60%. Studies with CE-tUS have demonstrated 
that NET have hyper-vascularity compared with hypo-vascularity of 
adenocarcinoma, or iso-vascularity of pancreatitis. Individual patient factors such 
as obesity and intestinal air are the most frequent limitations in scanning of the 
pancreas. 
Endoscopic ultrasound (EUS) has evolved over time into a diagnostic and 
therapeutic modality that has a major clinical impact on both digestive and 
mediastinal diseases. Nevertheless, the main indication of EUS has remained the 
diagnosis and staging of pancreatobiliary diseases, for which EUS is currently 
considered to be the first-choice examination. An accurate diagnosis cannot 
always be determined using only conventional B-mode EUS imaging. In many 
  
21 
 
cases, EUS-guided fine needle aspiration (FNA) and/or biopsy (FNB) can provide 
a definitive diagnosis.  
The accuracy of FNA has been demonstrated to be very high, with sensitivity 
between 80% and 85%, and specificity approaching 100%; however, EUS-guided 
tissue sampling is technically demanding, and multiple punctures may be 
necessary to obtain a sufficient amount of tissue. In addition, the sensitivity of 
cytology for malignancy is limited, and false-negative results are obtained in up 
to 20 % to 40 % of cases.  
FNB has not been shown to be superior to EUS-FNA for determining the etiology 
of pancreatic masses but should be considered if EUS-FNA is non-diagnostic and 
a histologic diagnosis is required. FNB is technically difficult for sampling of 
pancreatic head masses because of the stiffness of the needle and the acute 
angulation of the endoscope required for biopsy from this location. More-flexible 
needles have been developed recently that may circumvent this problem and allow 
better trans-duodenal sampling of pancreatic head masses that require core tissue 
to better determine the nature of the lesion. Potential adverse events from EUS-
guided sampling of pancreatic masses include a 0.5% to 2% risk of pancreatitis or 
bleeding. Tumor seeding with EUS-FNA has been reported, but the risk appears 
to be exceedingly small, and reports are currently limited to isolated cases (2). 
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Figure 1: a) EUS trans-gastric puncture of a pancreatic lesion.  b) EUS-needle. 
c) EUS-FNA. d) PA specimen at EUS-FNA 
  
 
 
The development of contrast-enhancement EUS (CE-EUS) and 
elastography has allowed a better characterization of focal pancreatic masses, with 
possible implications in the management of patients with negative EUS-FNA and 
a strong suspicion of malignancy.  
The contrast enhancement- EUS (CE-EUS) is not indicated to improve the 
detection of pancreatic lesions, but to improve the delineation and differential 
diagnosis of pancreatic lesions.  
One of the fluoro-gas-containing contrast agents used in CE-EUS is Sonovue®, 
which consists of phospholipids-stabilized bubbles of sulfurhexafluoride (SF6). 
Sonovue® is isotonic, stable and resistant to pressure, with a viscosity similar to 
blood. It does not diffuse into the extravascular compartment remaining within 
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the blood vessels until the gas dissolves and is eliminated in the expired air (blood 
pool contrast agent). The safety profile of SonoVue showed a very low incidence 
of side effects; it is not nephrotoxic and the incidence of severe hypersensitivity 
is similar to other magnetic resonance imaging contrast agents. Moreover, Sono-
Vue is approved for clinical use in EU countries.  
The blood supply of the pancreas is entirely arterial, making contrast-enhanced 
examinations feasible and readily available.  
Based on the European Federation Societies of Ultrasound in Medicine and 
Biology guidelines and recommendations, updated in 2008 and 2011, 2 phases 
were defined for CE-US and CEH-EUS of the pancreas: an early and/or arterial 
phase (starting from 10 to 30 seconds) and a late and/or venous phase (from 30 to 
120 seconds) (3, 4).  
An initial feasibility study showed that the specificity of the discrimination 
between benign and malignant focal pancreatic lesions is higher than 93.3% by 
using power Doppler contrast-enhanced EUS, as compared with 83.3% for 
conventional EUS. 
PA is typically hypo-enhanced in all phases compared with the adjacent 
pancreatic tissue, possibly because of the desmoplastic reaction and low mean 
vascular density. The hypo-enhanced aspect of lesions based CE-EUS seemed 
highly sensitive and specific (higher than 90%) for adenocarcinoma in several 
published studies, even in small lesions (5-7). In clinical practice there is still the 
problem of discrimination of focal lesions in chronic pancreatitis to PA due to the 
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similar vascularization behavior. CE-EUS, however, provided the possibility to 
analyze the macrovessels (arterioles and venoules) of the pancreas for 
neovascularization patterns. In fact PA shows an irregular vessel system in 
contrast to a netlike homogenous vessel system with both arterial and venous 
vessels in chronic pancreatitis. Using these criteria a discrimination sensitivity 
and specificity of over 90% can be achieved. 
NET present typically as hyperenhancing masses in the arterial phase, owing to 
their abundant arterial vascularization (8).  
Typical PA and NET behavior at CE-EUS are shown in Figure 2. 
 
Figure 2a: Typical aspect of hypo-enhanced PA at arterial phase 
  
Figure 2b: Typical aspect of hyper-enhanced NET at arterial phase 
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EUS-elastography is a recent ultrasound method used for the visualization 
and evaluation of tissue elasticity in real-time (9). Ultra-sonographic (US) waves 
travel at different speeds through tissues of different stiffness. Compression of 
tissue changes its mechanical properties and its reflection of US waves. A lesion 
may deform to a different degree in response to compression than surrounding 
normal tissue. Elastography compares the spatial arrangement of the tissue and 
the velocity of US waves at rest and after compression. When the tissue of a lesion 
is harder compared with the surrounding normal organ, the echoes will be less 
distorted than in the surrounding tissues and, after compression, the harder tissue 
will be less distorted than the softer tissue. The consequence is that US waves will 
travel at a higher fast through the hard mass (Figure 3). Inflammation and 
neoplastic infiltration lead to changes in normal tissue structure causing hardening 
of the tissue and alteration of its elasticity (10). 
 
Figure 3. 
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Elastography is broadly divided into two methodologies based on two different 
principles. One is “strain”, which is negatively correlated with tissue elasticity, 
and the other is “shear wave speed”, which is positively correlated with tissue 
elasticity. Currently, only strain elastography is available for use with EUS (11). 
Both longitudinal and radial echoendoscopes can be used for elastography, 
however, the former has the advantage that suspicious stiffer areas can be targeted 
for biopsy under direct visualization. 
The elasticity modulus is a measure of ‘stress’ applied to tissue structures, relative 
to the ‘strain’ or deformation produced (real-time tissue elastography, RTE). 
Thus, by calculating the elasticity of tissue, it is possible to differentiate benign 
(soft) tissue from malignant (hard) tissue (12). Ultrasound elastography was 
previously used for the diagnosis of non-digestive as well as digestive tumors: 
breast lesions, prostate cancer, thyroid nodules, rectal tumors. 
The pancreatic elastography can be performed by means of two different 
approaches, the percutaneous and the endoscopic. Most of the systems are set up 
to use a chromatic map (red–green–blue) in which hard tissue areas are shown in 
blue whilst soft tissue areas are displayed in red or green. The percutaneous 
approach is easy to perform, but has intrinsic limitations even related to the patient 
conformation and it is not really used. The echo-endoscopic approach is the most 
used nowadays for the elastographic study of the pancreas.  
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To obtain an elastographic image, echoendoscope is positioned and maneuvered 
according to the examined organs. The area to be evaluated is defined by a ROI 
(region of interest, color window). The size of the ROI that defines the 
elastographic image is very important. In fact the ROI should be sufficiently large 
to include both the pathological tissue under investigation and the surrounding 
reference tissue. The best image quality was recorded in phantom experiments 
when the lesion of interest covered 25%-50% of the ROI. In fact, when the ROI 
is too small, only the relative elasticity differences within the lesion is measured 
and displayed rather than the assessment of the lesion stiffness compared to the 
reference stiffness. Once the ROI is selected, a slight pressure can be applied by 
gently manipulating the probe. Normally very little additional compression is 
required, as the pressure difference from the pulsation of adjacent vessels is 
sufficient. The suitability of the elastographic signal is indicated by a numeric 
scale within the image. Elastographic and B-mode images are displayed 
simultaneously (13). 
There are two types of evaluation methods for EUS-elastography: the qualitative 
and quantitative evaluation.  
The qualitative method involves the evaluation of the pattern of the elastogram 
such as the major color tone and the heterogeneity of the color tones: elastography 
is shown in real time as transparent color images (red, green, and blue) in a region-
of-interest box that is superimposed over the conventional gray-scale b-mode 
EUS image, similar to color Doppler images.  
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Figure 4. A pancreatic ductal adenocarcinoma is demonstrated as a heterogeneous 
hard (blue) pattern. 
 
 
An elastic score was developed, based on the major color tone and the color tones’ 
heterogeneity. Score 1 was for a homogeneous hypoechoic area (soft, green), 
corresponding to the normal pancreatic tissue. Score 2 was assigned to 
heterogeneous elastographic images, but still within the soft-tissue range (green, 
yellow, and red), corresponding to fibrosis while score 3 was assigned to 
elastographic images that were largely blue (hard), with minimal heterogeneity, 
corresponding to a small, early pancreatic adenocarcinoma (less than 25 mm in 
diameter). Score 4 was assigned to lesions with a hypoechoic region in the center, 
with a green appearance in a small area, surrounded by blue or harder tissue, and 
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was interpreted as typical of hypervascular lesion such as a neuroendocrine tumor 
or small pancreatic metastasis. Score 5 was assigned to lesions that are largely 
blue on the elastogram but with heterogeneity including softer tissue colors 
(green, red), representing necrosis, and so corresponding to advanced pancreatic 
adenocarcinomas (14). The score is shown in Figure 5. 
 
Figure 5. 
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Another four score classification has been used by other authors, distinguishing 
homogeneous green pattern, heterogeneous green predominant pattern, 
heterogeneous blue predominant and homogeneous blue predominant pattern, 
corresponding respectively to normal pancreas, inflammatory pancreas, PA and 
malignant NET. (15). 
Since elastographic images and movies represent a qualitative type output that 
entails a subjective interpretation by the examiner, human bias is always 
susceptible to interfere with the results and diagnoses, due to color perception 
errors, moving artifacts, or possible selection bias induced by the analysis of still 
images. More objective, computer-assisted semi-quantitative means of 
interpreting the results were developed, but these have the disadvantage of being 
labor-intensive and using third-party software that cannot be used in real time. 
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The quantitative evaluation involves image analysis techniques that are used to 
evaluate the characteristics of a lesion in a quantitative manner. 
Three quantitative analysis methods have been used up to now: the strain ratio 
(SR), the strain histogram (SH) and the neural network. No consensus has been 
reached with regard to the superiority of each of these methods, but strain ratio 
and strain histogram remain the most used.  
Because strain (deformation) is smaller in harder tissues and larger in softer 
tissues, the differences in strain (hardness) of the tissues can be quantified and 
showed in real-time sono-elastography (16). 
The SR calculates the relative strain between two ROI, represented by the 
target area and a reference soft tissue area. Two different areas (A and B) are 
selected for quantitative elastographic analysis. Area A is selected so that it 
includes as much of the target lesion as possible without including the surrounding 
tissues. Area B is selected within a soft (red) reference area outside the target 
lesion, preferably the gut wall. The strain ratio is calculated as the quotient of B/A 
(17). 
 
Figure 6. Several studies have been conducted, showing high but variable 
sensitivity and specificity of the strain ratio with a wide span of cut-off values 
delineating inflammatory from malignant pancreatic masses (18-20).  
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Figure 5. Quantitative EUS elastography based on strain ratio analysis of a solid 
pancreatic mass (in this case a pancreatic adenocarcinoma). Area A represents 
pancreatic parenchyma, and area B to correspond to a soft area from the gut wall. 
The B/A ratio is displayed at the bottom of the image. 
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The SH is the graphical representation of the color distribution (hues) in a 
selected image field; hue histograms are based on data for a manually selected 
ROI within the standard elastography image. The ROI has to be sufficiently large 
to contain the area under examination and enough surrounding tissue for 
comparison. The optimum ratio is approximately 50% lesion, 50% 
normal/surrounding tissue. Based on software analysis, each pixel in the ROI is 
displayed with a hue that represents the relative strain value (hardness) of the 
tissue. SH measures the strain values of elemental areas inside a ROI and divides 
the measurement range into intervals; if the strain value of an element falls into 
an interval, its initial area normalized by the initial total surface area is added to 
the running total of that interval; the total values of each interval are used to 
produce a graph and an average value. 
New technical developments allow averaging over several frames in order to 
calculate the mean hue histogram value that corresponds to global tissue elasticity 
within a selected area. Several studies have been conducted, showing high but 
variable sensitivity and specificity of the mean SH with a wide span of cut-off 
values delineating inflammatory from malignant pancreatic masses (6, 21, 22). 
An example of SH is shown in Figure 6. 
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Figure 6. Quantitative EUS elastography based on strain histogram analysis of a 
solid pancreatic mass (chronic pseudotumoral pancreatitis in the upper part and 
pancreatic adenocarcinoma in the lower part). The histogram (at the bottom of 
each figure) shows the elastographic colour dispersion in the region of interest 
and also gives the mean of elasticity (in a range from 0 to 255). In case of 
pseudotumoral chronic pancreatitis the aspect of hardness of at elastography is 
mixed (mostly green and blue), while in the case of PA is hard (blue). 
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A new variable was introduced by Opacic in 2015, the strain histogram ratio 
(SHR). This value was calculated by dividing the mean SH calculated over the 
mass and over an adjacent part of homogenous pancreatic tissue representing a 
reference area (23). An example of SH with SHR is shown in Figure 7. 
 
Figure 7. Quantitative EUS elastography with SH ratio calculated dividing the 
mean SH obtained over the pancreatic mass (Mode 1) and the mean SH over an 
adjacent part of homogenous pancreatic tissue (Mode 2). 
 
  
36 
 
Aims of the study 
  
The aim of the present study was to use the quantitative elastography (using the 
new technique of “strain histogram”) to: 
• quantify the EG pattern of normal pancreas. 
• quantify the EG pattern of solid malignant pancreatic masses. 
• differentiate within malignant pancreatic masses (adenocarcinoma vs 
NET). 
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Materials and methods 
This was a prospective, consecutive, descriptive 18-months study 
comparing CE-EUS and elastography results for the characterisation of focal 
pancreatic masses, in comparison with the gold standard represented by 
pathology. 
  
 Inclusion criteria 
 Patients diagnosed with solid pancreatic tumor masses, with 
cytological/histo-logical confirmation. Only patients presenting PA or 
NET were included in the final analysis. NET were defined by anatomo-
pathologist according to their mitotic count and Ki67 into grade 1, grade 
2 and grade 3. 
 Patients undergoing EUS-exploration during the study period because 
of extrapancreatic diseases and presenting with a normal pancreas at 
EUS were randomly selected and included as controls to describe the 
elastographic appearance of the healthy pancreas. 
 Age 18 to 90 years old, men or women. 
 From May 2014 to December 2015. 
 At the EUS Unit of the Department of Gastroenterology of the Institut 
Paoli Calmettes. 
 Signed informed consent for EG-EUS, CE-EUS and FNA biopsy. 
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 Exclusion criteria 
 Prior surgical treatment with curative intent or chemo-radiotherapy. 
 Patients diagnosed with mucin producing tumors, pancreatic cystic 
tumors, etc. 
 
 Data collection  
 Personal data (name, surname, age, weight, admission date, diagnosis at 
admission). 
 Lesions (presence/absence, position and size, histology). 
 
 Imaging tests 
All patients with a suspicion of pancreatic masses underwent EUS with 
FNA with sequential CE-EUS and EG-EUS. 
 EUS was performed with linear instrument with complete 
examinations of the pancreas. Tumor characteristics (echogenicity, 
echostructure, size) were described as well as presence/absence of 
power Doppler signals. EUS-FNA was performed in all pancreatic 
masses with at least three passes. 
 CE-EUS was performed with a two panel image (conventional gray-
scale B-mode EUS image on the right side and contrast harmonic 
image on the left side). 
  
39 
 
The starting point of the timer was considered the moment of 
intravenous contrast injection (Sonovue 4.8 mL). The whole movie 
of one minute (T0-T60s) was recorded on the embedded HDD of the 
ultrasound system, for later analysis. 
We defined the enhancement as “typical of PA” when lesion 
appeared as hypovascularized, “typical of NET” when lesions 
appeared as hypervascularized and atipycal when the presented a 
weekly enhancement in the early phase (from 10 to 30 seconds from 
the injection of SonoVue and flushing). 
 EUS-EG was performed during usual EUS examinations, with three 
movies of 10 seconds recorded on the embedded HDD in order to 
minimize variability and to increase repeatability of acquisition. 
A two panel image with the usual conventional gray-scale B-mode 
EUS image on the right side and with the elastography image on the 
left side was used.  
The region of interest for EUS-EG was chosen as preferably larger 
than the focal mass (approximately 50%-50%), in order to include 
the surrounding structures. If the focal mass was larger than 3 cm, 
part of the mass was included in the ROI, as well as the surrounding 
structures (preferably avoiding large vessels). Very large ROI for the 
elastography calculations were avoided due to the risk of appearance 
of side artifacts.  
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The following pre-settings were used: elastography colour map 1, 
frame rejection 2, noise rejection 2, persistence 3, dynamic rage 4, 
smoothing 2, blend 50%. 
Strain histograms (SH) was measured; with three measurements 
made and recorded on the embedded HDD. The following 4 
parameters were calculated using the histogram to quantify the 
elasticity of the pancreas: mean (the arithmetic mean on this 
histogram, with a higher value indicating soft tissue), classified in a 
scale from 0 to 255; standard deviation (a measure of the spread of 
values on the histogram, with a higher value indicating 
heterogeneous hardness); skewness (a measure of the asymmetry of 
the histogram, with a higher value indicating hard tissue) and 
kurtosis (a measure of the ‘‘peakedness’’ of the histogram, with a 
higher value indicating a concentration of specific hardness)  
Interpretation of strain histogram 
The x-axis in a hue histogram represents tissue elasticity expressed 
numerically, and the height of the spikes displayed in the y-axis 
indicates the number of pixels of each elasticity level found in the 
ROI. 
 
 Final diagnosis  
Commenté [U1]:  
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Histology of surgical specimens was considered as the reference method in 
operated cases. 
A positive cytology for malignancy and compatible EUS and CT imaging were 
considered the reference method in unresectable tumors. 
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Statistical analysis 
All results were expressed as mean ± standard deviation (SD).  
Differences between the patients with pancreatic cancer and normal pancreas 
were performed by the two-sample t-test (two independent samples). Sensitivity, 
specificity, positive predictive value, negative predictive value and accuracy of 
EG-EUS were determined in comparison with the final diagnosis. 
Diagnostic accuracy of quantitative EUS–elastography based on strain histogram 
for detecting malign lesions was calculated after drawing the corresponding 
receiver operating characteristic (ROC) curve analysis, with specific values for 
the area under the curve, the significance of the area, and confidential intervals. 
Based on ROC curve analysis, a cut-off point was selected as the point of the 
curve closest to the upper left corner of the graphic, where sensitivity and 
specificity are equal to 1.0. 
Sensitivity (SS), specificity (SP), positive and negative predictive values, and 
positive and negative likelihood ratios are also expressed in the analysis. 
The calculation of the overall accuracy (ACC) of the prediction was based on 
previous parameters.  
The positive likelihood ratio is calculated as sensitivity/1 - specificity. The 
negative likelihood ratio is calculated as 1- specificity/sensitivity. 
The overall accuracy is calculated as the sum of the positive and negative 
predictive values. 
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Statistical significance is set to p < 0.05, with all confidence intervals expressed 
at the 95% level. 
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Results 
 
 Patients’ characteristics 
A total of 80 patients were included in the study. Of these only 63 were 
included in the statistical analysis. The other patients were excluded because they 
presented pancreatic lesions different from PA and NET (intrapapillary mucinous 
neoplasia, lesions of chronic pancreatitis, others). 
Patient’s characteristics are described in Table 2. 
 
In 4 patients, these was the second (or more) EUS + FNA, due to non-conclusive 
or false negative results in previous FNA. 
Within PA group, 4 patients presented, according to TNM staging, a stage 1 PA, 
5 patients a stage 2a PA, 2 patients a stage 2b PA, 7 patients a stage 3 PA and the 
last 27 patients a stage 4 PA. 
Within NET group, 4 patients presented at histology a grade 1 tumor, while 5 
patients a grade 2/3. 
Sex, M (%) 32 4 25 3
Age, mean (range) 64 (19-88) 51 (19-69) 68(48-88) 57(20-76)
Height, mean (range): m 1,6 (1,5-1,8) 1,6 (1,5-1,7) 1,6 (1,5-1,8) 1,6 (1,5-1,8)
Weight, mean (range): Kg 70 (44-128) 80 (48-103) 68 (44-128) 72 (58-110)
BMI, mean (range) 25 (16-43) 28 (19-40) 24 (16-41) 25 (19-43)
Smoking, number (%) 14 0 13 1
Alcool, number (%) 3 0 3 0
Lesion position:
head 20 19 1
body 22 18 4
tail 12 8 4
Lesion max diameter, mean 
(range)
35 (9-76) n.a. 36 (15-60) 31 (9-76)
Table 2: Patients caracteristics
All (n=63)
Normals pancreas 
(n=9)
n.a.
Pancreatic NET (n=9)
Pancreatic 
adenocarcinoma 
(n=45)
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 CE-EUS 
CE-EUS was performed in all the 54 patients presenting a pancreatic mass. 
Enhancement behavior was compared with histological results. Between patients 
with a histological diagnosis of PA, 15% presented an atypical enhancement for 
PA. All patients with NET presented a “typical for NET” enhancement (Figure 
8). Results are shown in Table 3.  
 
 
 
Figure 8. A typical PA (on the top) and NET (on the bottom) behavior at CE-
EUS. 
 
Hypoenhanced: typical of pancreatic 
adenok
38 38 0
Hyperenhanced: typical of NET 14 5 9
Atypical 2 2 0
All (n=54)
Pancreatic 
adenocarcinoma 
(n=45)
Pancreatic NET 
(n=9)
Table 3: CE-EUS. Pancreatic adenocarcinoma vs. P-NET
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 Elastrography 
Elastography was performed in all patients. A strain histogram of a patients with 
normal pancreas, of a patients with NET and of a patient with PA are shown in 
Figure 9. 
 
Figure 9. Normal pancreas (top), PA (middle) and NET (bottom) aspect are 
shown. 
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 Comparison between normal pancreas and malignant 
pancreatic masses 
A comparison between normal pancreas and malignant pancreatic masses (PA + 
NET grade 2/3) was performed, showing a statistically significant difference in 
all the parameters examined. Data are shown in Table 4  
 
 
The univariate analysis was performed, and the diagnostic accuracy of all the 
quantitative EUS–elastographic measured was calculated. Data are shown on  
  
Paramethers  Normal pancreas
Malignant pancreatic 
lesions (adenocarcinoma + 
NET 2/3)
p-values
Mean SH 95.2 30.04 <0.001
Standard Deviation 51.31 34.98 <0.001
Skewness 0.78 2.19 <0.001
Kurtosis 4.16 10.12 <0.001
Table 4. EUS-EG. Normal pancreas vs. Malignant pancreatic masses.
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Table 5. 
 
 
 
A cut-off was calculated for each measure to differentiate between malignant and 
benign pancreatic masses, showing to be statistically significant. Data are shown 
on Figures 10-13.  
Paramethers Odds ratio [CI 95%] AUC [CI 95%] Cut-off p-values
Mean SH
0.928 
[0.890 ; 0.967]
0.933 
[0.869 ; 0.997]
43.250 0.0004
Standard 
Deviation
0.906 
[0.852 ; 0.963]
0.813 
[0.709 ; 0.918]
44.633 0.0015
   Skewness
7.316 
[2.573 ; 20.804]
0.876 
[0.762 ; 0.991]
1.505 0.0002
Kurtosis
1.616 
[1.199 ; 2.178]
0.882 
[0.766 ; 0.998]
5.080 0.0016
Table 5: EUS-elastography. Normal pancreas vs malignant pancreatic masses.
Univariate analysis 
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Figure 10. Comparison between normal pancreas and malignant pancreatic 
masses, Mean SH 
 
 
Figure 11. Comparison between normal pancreas and malignant pancreatic 
masses, Standard Deviation SH 
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Figure 12. Comparison between normal pancreas and malignant pancreatic 
masses, Shewness SH 
 
 
Figure 13. Comparison between normal pancreas and malignant pancreatic 
masses, Kurtosis SH 
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At multivariate analysis only the mean SH resulted as statistically capable to 
differentiate between benign and malignant pancreatic masses. Data are shown on 
Table 6. 
 
 
 
At logistic regression a statistical model was constructed to differentiate normal 
pancreas and malignant pancreatic masses.  
The model is the following: 
9.8958 – 0.3170*mean + 0.2989*SD + 0.7935*kurtosis – 7.0642*skewness. 
AUC: 0.933 [0.850 ; 1.000] 
A cut-off of 0.570 was detected, with lower or equal values corresponding to 
benign pancreas and higher value corresponding to malignant pancreas. 
Using this model, we found a sensibility, specificity and accuracy of 95.23%, 
97.96% and 85.71% respectively. Data are shown on Figure 12. 
 
  
Paramethers Odds ratio [CI 95%] p-values
Mean SH 0.728 [0.550 ; 0.965] 0.0270
Standard Deviation 1.348 [0.988 ; 1.841] 0.0598
Skewness <0.001 [<0.001 ; 11.141] 0.2027
Kurtosis 2.211 [0.652 ; 7.495] 0.1439
Table 6: EUS-elastography. Normal pancreas vs malignant pancreatic masses.
Multivariate analysis 
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Figure 12. Linear Predictor 
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 Comparison within malignant pancreatic masses (PA and NET)  
 
A comparison within malignant pancreatic masses was therefore performed, 
showing no statistically significant differences to distinguish PA from malignant 
NET. Data are shown on Table 7. 
 
 
 
A cut-off was calculated for each measure to differentiate within malignant PA 
and NET, showing to be not statistically significant. Data are shown on Figures 
13-16. 
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Figure 13. Comparison within malignant pancreatic masses (PA and NET grade 
2/3), Mean SH. 
 
Figure 14. Comparison within malignant pancreatic masses (PA and NET grade 
2/3), SD SH. 
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Figure 15. Comparison within malignant pancreatic masses (PA and NET grade 
2/3), Skewness SH. 
 
Figure 16. Comparison within malignant pancreatic masses (PA and NET grade 
2/3), Kurtosis SH. 
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Conclusions 
EUS represents one of the most reliable and accurate techniques for the diagnosis 
and staging of pancreatic cancer. However, the differential diagnosis of solid 
pancreatic masses remains a challenge in clinical work.  
For that reason, EUS-FNA has been introduced, obtaining high specificity (close 
to 100%) and good sensibility (from 80 to 85%). On the other way, EUS-FNA is 
associated with several difficulties such as the prolonged learning curve and the 
need, in same case, of several punctures to obtain an adeguate sample. 
Furthermore EUS-FNA can be associated to iatrogenic complications, such as 
acute iatrogenic pancreatitis, bleeding and infections.  
CE-EUS has improved the differential diagnosis within malignant 
pancreatic masses. Several studies have been conducted to evaluate the efficacy 
of CE-EUS in the diagnosis of pancreatic neoplasia.  
For PA, studies showed a sensitivity of 91%, a specificity of 93% with positive 
and negative predictive value of 100 and 88% respectively (7). 
CE-EUS is very advantageous for the detection of NET, that can present variably 
as hypo to iso to hyper-echoic. Classically, these tumors are hyper-vascular, 
therefore clearly visible after the contrast administration as a hyper-enhancing 
mass at the arterial phase. The presence of filling defects within an enhancing 
pancreatic lesion frequently corresponds to hemorrhage or necrosis of malignant 
diseases at pathological examination. This may have a potential role in 
differentiating benign versus malignant NET. The ability to distinguish a NET by 
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imaging, without the need for FNA, is useful for several reasons. In fact, 
therapeutic enucleation procedures may be hampered if FNA is performed. 
Secondly, adequate tissue acquisition may be difficult in small lesions. The 
decision for or against FNA depends on the single patient, as there may be 
prognostic implications to cytology results (24). 
Differential diagnosis between PA and NET at CE-EUS remains still difficult. 
Even in our experience, we found that 15.5% of patients with histological 
diagnosis of PA presented a partial enhancement or a hyper-enhancement at 
arterial phase.  
The limitations of FNA and CE-EUS have required the development of new 
techniques. 
For that reason EUS-elastography has been developed, at the beginning as 
a qualitative technique and now as a quantitative measure. 
The first study on qualitative elastometry was published in 2006 by 
Giovannini et al. In this study 24 patients with a pancreatic mass and 25 patients 
with lymph nodes underwent EUS examination and elastography. Masses or 
lymph nodes that appeared mostly blue (harder) were considered to be malignant, 
while others were regarded as benign. The final diagnosis was based on the 
histological assessment of the FNA samples and surgical specimens, when 
available. The sensitivity and specificity of elastography in the diagnosis of 
malignant lesions were 100% and 67%, respectively. In the same study the author 
developed a five score classifications, based on elastographic findings, able to 
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distinguish between normal pancreas, fibrotic pancreas (corresponding to chronic 
pancreatitis), neuro endocrine tumors and initial or advanced pancreatic 
adenocarcinoma (14). 
In a subsequent multi-centric study published by the same author, the sensitivity, 
specificity, positive and negative predictive values of qualitative EUS 
elastography to differentiate benign from malignant pancreatic masses were 
evaluated, resulting 92.3%, 80.0%, 93.3% and 77.4% respectively, with a global 
accuracy of 89.2%. The authors affirmed that the goal of elastography was not to 
replace citologycal or histological confirmation. Instead, the information obtained 
could be complementary to the conventional EUS imaging and could orientate 
further exploration rather than immediate surgery or conservative management in 
case of repeated negative EUS-FNA (25). 
Another 4 variables score (based on colour predominance pattern) was created by 
other authors. Based on this score the diagnostic sensitivity, specificity and overall 
accuracy of EUS elastography for diagnosing malignancy corresponded to 100%, 
85.5% and 94%, respectively (15). 
Similar studies were conducted showing a sensitivity between 41 and 100%, a 
specifity between 53 and 85%, a positive and negative predictive values around 
90% and an accuracy between 45 and 94% (15, 26-28). In particular results from 
a study by Janssen et al were particularly disappointing, and the authors concluded 
that chronic pancreatitis and hard malignant tumors cannot be distinguished by 
elastography, probably due to their similar fibrous structure (26). On the contrary, 
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a more recent study conducted by Iglesias-Garcia et al. showed a very good 
correlation between observers by analyzing the videos recorded from 258 patients 
with chronic pancreatitis and pancreatic cancer (21). A review of the literature 
regarding qualitative elastometry is shown in Table 8. 
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Considering the limitations related to the qualitative, mostly due to 
perception errors and the inability of the human eye to completely characterize all 
color hues, the quantitative elastometry has been introduced. 
The first study was published by Saftoiu et al in 2008. Sixty-height patients were 
enrolled, of whom 22 presented a normal pancreas and the others chronic 
pancreatitis (11), PA (32) and NET (3). A post-processing software analysis was 
used to examine the EUS elastography movies by calculating the strain histograms 
mean value of each individual image. Data that were further subjected to an 
extended neural network analysis to differentiate benign from malignant 
patterns. Based on a cutoff of 175 for the mean strain histogram value recorded 
on the region of interest, the sensitivity, specificity, and accuracy of 
differentiation of benign and malignant masses were 91.4%, 87.9%, and 89.7%, 
respectively. The positive and negative predictive values were 88.9% and 90.6%, 
respectively (22). 
Others studies used the mean strain histogram value, showing a sensitivity 
between 75 and 91%, a specificity between 78 and 95%, a positive and negative 
predictive values around 90% and 70% respectively and an accuracy between 79 
and 89% (6, 21). 
The first study using strain ratio was conducted by Iglesias-Garcia in 
2010. One-hundred and six patients were enrolled, of whom 49 presented 
pancreatic adenocarcinoma (49), and the others inflammatory mass (27), 
malignant NET (6), metastatic oat-cell lung cancer (2), pancreatic lymphoma (1), 
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and pancreatic solid pseudopapillary tumor (1). The strain ratio was significantly 
higher among patients with pancreatic malignant tumors compared with those 
with inflammatory masses. The sensitivity and specificity of strain ratio for 
detecting pancreatic malignancies were 100% and 92.9%, respectively (area under 
the receiver operating curve, 0.983) (29).  
Others studies used the strain ratio, with cut off ranging from 3.17 to 6.04, 
showing a sensitivity between 86 and 100%, a specificity between 33 and 92%, a 
positive and a negative predictive values of 89% and 60% respectively and an 
accuracy of 81% (19, 20, 30, 31). 
In 2015 Opacic et al. introduced the SH ratio (SHR), a new variable calculated by 
dividing the mean SH over a lesion and the mean SH over a reference area. The 
traditional mean SH showed in this study a high sensitivity in pancreatic 
malignant tumor detection but disappointingly low specificity. Slight 
improvements in specificity and accuracy were achieved using the SHR. The SHR 
reached 98% sensitivity, 50% specificity and an overall accuracy of 69% (95%CI: 
63%-70%). The positive and negative predictive values were 92% and 100%, 
respectively (23). 
A review of the literature regarding quantitative elastometry is shown in Table 9. 
  
  
64 
 
 
Evalu
atio
n
N
 o
f to
tal 
p
atie
n
ts
N
 o
f p
atie
n
ts 
w
ith
 p
an
cre
atic m
asse
s
Se
n
sitivity
Sp
e
cificity
P
P
V
N
P
V
A
ccu
racy
In
te
ro
b
se
rve
r 
agre
e
m
e
n
t (k)
n
o
te
s
Safto
iu
 A
,
G
astro
in
testin
al En
d
o
sco
p
y
2
0
0
8
m
o
n
o
cen
tric
n
eu
ral n
etw
o
rk 
an
alysis + strain
 h
isto
gram
(cu
t o
ff: 1
7
5
)
6
8
3
5
( 3
2
 ad
en
o
carcin
o
m
a 3
 N
ET)
9
1
,4
8
7
,9
8
8
,9
9
0
,6
8
9
,7
n
.a.
Igle
sias-G
arcia J,
G
astro
en
tero
lo
gy,
2
0
1
0
m
o
n
o
cen
tric
strain
 ratio
 
(cu
t o
ff: 6
,0
4
)
8
6
8
6
(4
9
 ad
en
o
carcin
o
m
a, 2
7
 in
flam
m
ato
ry m
ass, 6
 N
ET 
6
 m
ts, 1
 lym
p
h
o
m
a, 1
 so
lid
 p
seu
d
o
p
ap
illary tum
o
r)
1
0
0
9
2
,9
n
.a.
n
.a.
n
.a.
n
.a.
Safto
iu
 A
,
G
astro
in
testin
al En
d
o
sco
p
y
2
0
1
0
m
o
n
o
cen
tric
co
n
trast-en
h
an
ced
 P
D
V
I  (cu
t 
o
ff 2
0
%
) + strain
 h
isto
gram
  
(cu
t o
ff: 1
7
5
)
5
4
5
4
 
(3
3
 ad
en
o
carcin
o
m
a
2
1
 ch
ro
n
ic p
an
crea
titis)
7
5
,8
9
5
,2
9
6
,2
7
1
,4
8
3
,3
n
.a.
b
etw
ee
n
 ch
ro
n
ic 
p
seu
d
o
tum
o
ral
p
an
crea
titis an
d
 p
an
crea
tic 
can
cer
Ito
kaw
a F,
J G
astro
en
tero
l
2
0
1
1
m
o
n
o
cen
tric,
retro
spective
strain
 ratio
 
1
0
9
8
1
(7
2
 ad
en
o
carcin
o
m
a,
9
 N
ET)
n
.a.
n
.a.
n
.a.
n
.a.
n
.a.
n
.a.
Safto
iu
 A
,
En
d
o
sco
p
y
2
0
1
1
m
u
lticen
tric,
p
ro
spective
strain
 h
isto
gram
(cu
t o
ff strain
 h
isto
gram
: 
1
8
5
) 
2
5
8
2
5
8
(2
1
1
 ad
en
o
carcin
o
m
a,
4
7
 ch
ro
n
ic p
an
crea
titis)
7
9
,2
7
8
,7
9
4
,4
4
5
,7
7
9
,1
n
.a.
b
etw
ee
n
 ch
ro
n
ic 
p
seu
d
o
tum
o
ral
p
an
crea
titis an
d
 p
an
crea
tic 
can
cer
D
aw
w
as M
F,
G
astro
in
testin
al En
d
o
sco
p
y
2
0
1
2
m
o
n
o
cen
tric
strain
 ratio
(cu
t o
ff: 6
,4
5
)
1
0
4
1
0
4
(7
4
 ad
en
o
carcin
o
m
a,
1
1
 N
ET, 2
 m
ts, 1
7
 p
an
crea
titis)
1
0
0
1
6
,7
8
6
,1
1
0
0
8
6
,5
n
.a.
H
o
cke
 M
,
Z G
astro
en
tero
l
2
0
1
2
m
o
n
o
cen
tric
?
5
8
5
8
 
(1
9
 ad
en
o
carcin
o
m
a
3
9
 ch
ro
n
ic p
an
crea
titis)
9
4
,7
3
3
,4
n
.a.
n
.a.
n
.a.
n
.a.
b
etw
ee
n
 ch
ro
n
ic 
p
seu
d
o
tum
o
ral
p
an
crea
titis an
d
 p
an
crea
tic 
can
cer
Le
e
 Th
,
C
lin
 En
d
o
sc
2
0
1
3
m
o
n
o
cen
tric
strain
 ratio
 
(n
o
 cu
t o
ff)
3
5
1
5
(1
4
 ad
en
o
carcin
o
m
a
1
 p
seu
d
o
cyst)
n
.a.
n
.a.
n
.a.
n
.a.
n
.a.
n
.a.
b
etw
ee
n
 p
an
crea
tic m
asses 
an
d
 co
n
tro
ls p
an
crea
titis an
d
 
p
an
crea
tic can
cer
D
yrla P
,
P
rz G
astro
en
tero
l. 
2
0
1
5
m
o
n
o
cen
tric
n
.a.
8
0
5
4
( 3
4
 ad
en
o
carcin
o
m
a,
2
0
 p
an
crea
tic p
seu
d
o
tum
o
rs)
n
.a.
n
.a.
n
.a.
n
.a.
n
.a.
n
.a.
K
o
n
gkam
 P
,
J G
astro
en
tero
l H
ep
ato
l
2
0
1
5
m
o
n
o
cen
tric
strain
 ratio
 
(cu
t o
ff: 3
,1
7
)
3
8
3
8
 
(2
3
 ad
en
o
carcin
o
m
a, 5
 N
ET, 1
 M
TS, 2
 p
an
crea
tic 
p
seu
d
o
tum
o
r, 3
 A
IP
, 4
 o
thers)
8
6
,2
6
6
,7
8
9
,3
6
0
8
1
,6
n
.a.
O
p
acic D
,
W
o
rld
 J G
astro
en
tero
l
2
0
1
5
m
o
n
o
cen
tric
strain
 h
isto
gram
 ratio
(cu
t o
ff : 1
,1
5
3
)
1
4
9
1
0
5
(5
8
 ad
en
o
carcin
o
m
a,
4
7
 p
an
crea
tic p
seu
d
o
tum
o
r)
9
8
5
0
9
2
1
0
0
6
9
n
.a.
Tab
le
 9
: R
e
vie
w
 o
f th
e
 litte
ratu
re
. Q
U
A
N
TITA
TIV
E e
lasto
grap
h
y.
  
65 
 
In our study we evaluated the capacity of 4 derived SH values (mean SH, 
standard deviation, skewness and kurtosis), singularly and combined, to 
differentiate between normal pancreas and malignant pancreatic masses. At 
univariate analysis all the 4 different parameters resulted statistically effective in 
the differential diagnosis. At multivariate analysis only mean SH reached the 
statistically difference, confirming the results of previous studies. 
We even evaluated if SH variables were capable to differentiate within malignant 
pancreatic masses (between PA and NET), but results were non statistically 
significant at both univariate and multivariate analysis. We believe that our results 
could have been influenced by the limited number of NET enrolled in the study 
and that this statement should be confirmed by a larger size study. 
The real innovation of our study is the construction of a statistical model that 
integrated the 4 quantitative variables obtained by SH to differentiate malignant 
pancreatic masses from normal pancreas. We obtained a cut-off of 0.57. This cut-
off seems to be capable to distinguish benign pancreas and malignant pancreatic 
masses, with a very high sensitivity and specificity. 
The main limitation of our study was, as already said, the low number of patients 
enrolled with NET. This is absolutely concordant with the real life, where NET 
account for only 1% of pancreatic cancer by incidence and PA as 90%, and with 
population of previous published studies. We decided not to include in our study 
degenerated IPMNs or other cystic malignant lesions due to their appereance at 
elastography as artifact, i.e., BGR (blue-green-red) artifact. Unlikely, the use of 
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elastography for IPMNs seems limited, but the number of EUS + FNA for IPMNs 
degeneration’s surveillance is increasing in parallels with the increased discover 
of these lesions. 
Based on the results of our study, a strong suspicion of pancreatic cancer should 
be retained for values of the strain histogram multivariate model analysis higher 
than 0.57. We believe that actual knowledge on elastography is still insufficient 
to replace FNA or FNB with this technique. Therefore we believe that EUS-EG 
should be used in case of patients with pancreatic masses but multiple negative 
EUS–FNA (up to 25% of FNA), and/or atypical CE-EUS (hyper-enhancement or 
late enhancement).  
We propose this model: patients with negative EUS–FNA (and eventually an 
atypical CE-EUS) and value lower than 0.57 should be followed up; patients with 
negative EUS–FNA (and eventually an atypical CE-EUS) and value higher than 
0.57 should repeat EUS–FNA and/or undergo surgery. 
Our results should be validated by a multicentre high volume study, even 
comparing benign and malignant pancreatic masses. 
Future developments of EUS elastography for pancreatic related 
pathologies concern the elastography-guided biopsy of the pancreas and the 
cancer staging Evenmore EUS elastography is very sensitive in detecting even 
very small lesions and could improve the accuracy of EUS +/- CE-EUS. The 
additional value of elastography combined with other techniques such as contrast-
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enhanced endoscopic ultrasound (CE-EUS), fusion imaging or 3D elastography 
examinations might also be feasible. 
  
  
68 
 
References 
1. Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, et al. 
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. 
Gastroenterology. 2012;142(4):796-804; quiz e14-5. 
2. Committee ASoP, Eloubeidi MA, Decker GA, Chandrasekhara V, 
Chathadi KV, Early DS, et al. The role of endoscopy in the evaluation and 
management of patients with solid pancreatic neoplasia. Gastrointestinal 
endoscopy. 2016;83(1):17-28. 
3. Claudon M, Cosgrove D, Albrecht T, Bolondi L, Bosio M, Calliada F, et 
al. Guidelines and good clinical practice recommendations for contrast enhanced 
ultrasound (CEUS) - update 2008. Ultraschall in der Medizin. 2008;29(1):28-44. 
4. Piscaglia F, Nolsoe C, Dietrich CF, Cosgrove DO, Gilja OH, Bachmann 
Nielsen M, et al. The EFSUMB Guidelines and Recommendations on the Clinical 
Practice of Contrast Enhanced Ultrasound (CEUS): update 2011 on non-hepatic 
applications. Ultraschall in der Medizin. 2012;33(1):33-59. 
5. Dietrich CF, Ignee A, Braden B, Barreiros AP, Ott M, Hocke M. Improved 
differentiation of pancreatic tumors using contrast-enhanced endoscopic 
ultrasound. Clinical gastroenterology and hepatology : the official clinical 
practice journal of the American Gastroenterological Association. 2008;6(5):590-
7 e1. 
6. Saftoiu A, Iordache SA, Gheonea DI, Popescu C, Malos A, Gorunescu F, 
et al. Combined contrast-enhanced power Doppler and real-time 
  
69 
 
sonoelastography performed during EUS, used in the differential diagnosis of 
focal pancreatic masses (with videos). Gastrointestinal endoscopy. 
2010;72(4):739-47. 
7. Hocke M, Schulze E, Gottschalk P, Topalidis T, Dietrich CF. Contrast-
enhanced endoscopic ultrasound in discrimination between focal pancreatitis and 
pancreatic cancer. World journal of gastroenterology. 2006;12(2):246-50. 
8. Dietrich CF, Sharma M, Hocke M. Contrast-enhanced endoscopic 
ultrasound. Endoscopic ultrasound. 2012;1(3):130-6. 
9. Frey H. [Realtime elastography. A new ultrasound procedure for the 
reconstruction of tissue elasticity]. Der Radiologe. 2003;43(10):850-5. 
10. Pedrosa MC, Barth BA, Desilets DJ, Kaul V, Kethu SR, Pfau PR, et al. 
Enhanced ultrasound imaging. Gastrointestinal endoscopy. 2011;73(5):857-60. 
11. Ohno E, Kawashima H, Hashimoto S, Goto H, Hirooka Y. Current status 
of tissue harmonic imaging in endoscopic ultrasonography (EUS) and EUS-
elastography in pancreatobiliary diseases. Digestive endoscopy : official journal 
of the Japan Gastroenterological Endoscopy Society. 2015;27 Suppl 1:68-73. 
12. Garra BS, Cespedes EI, Ophir J, Spratt SR, Zuurbier RA, Magnant CM, et 
al. Elastography of breast lesions: initial clinical results. Radiology. 
1997;202(1):79-86. 
13. Cui XW, Chang JM, Kan QC, Chiorean L, Ignee A, Dietrich CF. 
Endoscopic ultrasound elastography: Current status and future perspectives. 
World journal of gastroenterology. 2015;21(47):13212-24. 
  
70 
 
14. Giovannini M, Hookey LC, Bories E, Pesenti C, Monges G, Delpero JR. 
Endoscopic ultrasound elastography: the first step towards virtual biopsy? 
Preliminary results in 49 patients. Endoscopy. 2006;38(4):344-8. 
15. Iglesias-Garcia J, Larino-Noia J, Abdulkader I, Forteza J, Dominguez-
Munoz JE. EUS elastography for the characterization of solid pancreatic masses. 
Gastrointestinal endoscopy. 2009;70(6):1101-8. 
16. Dietrich CF, Saftoiu A, Jenssen C. Real time elastography endoscopic 
ultrasound (RTE-EUS), a comprehensive review. European journal of radiology. 
2014;83(3):405-14. 
17. Iglesias-Garcia J, Lindkvist B, Larino-Noia J, Dominguez-Munoz JE. 
Endoscopic ultrasound elastography. Endoscopic ultrasound. 2012;1(1):8-16. 
18. Iglesias-Garcia J, Larino-Noia J, Abdulkader I, Forteza J, Dominguez-
Munoz JE. Quantitative endoscopic ultrasound elastography: an accurate method 
for the differentiation of solid pancreatic masses. Gastroenterology. 
2010;139(4):1172-80. 
19. Itokawa F, Itoi T, Sofuni A, Kurihara T, Tsuchiya T, Ishii K, et al. EUS 
elastography combined with the strain ratio of tissue elasticity for diagnosis of 
solid pancreatic masses. Journal of gastroenterology. 2011;46(6):843-53. 
20. Dawwas MF, Taha H, Leeds JS, Nayar MK, Oppong KW. Diagnostic 
accuracy of quantitative EUS elastography for discriminating malignant from 
benign solid pancreatic masses: a prospective, single-center study. 
Gastrointestinal endoscopy. 2012;76(5):953-61. 
  
71 
 
21. Saftoiu A, Vilmann P, Gorunescu F, Janssen J, Hocke M, Larsen M, et al. 
Accuracy of endoscopic ultrasound elastography used for differential diagnosis 
of focal pancreatic masses: a multicenter study. Endoscopy. 2011;43(7):596-603. 
22. Saftoiu A, Vilmann P, Gorunescu F, Gheonea DI, Gorunescu M, Ciurea T, 
et al. Neural network analysis of dynamic sequences of EUS elastography used 
for the differential diagnosis of chronic pancreatitis and pancreatic cancer. 
Gastrointestinal endoscopy. 2008;68(6):1086-94. 
23. Opacic D, Rustemovic N, Kalauz M, Markos P, Ostojic Z, Majerovic M, et 
al. Endoscopic ultrasound elastography strain histograms in the evaluation of 
patients with pancreatic masses. World journal of gastroenterology. 
2015;21(13):4014-9. 
24. Mohamed RM, Yan BM. Contrast enhanced endoscopic ultrasound: More 
than just a fancy Doppler. World journal of gastrointestinal endoscopy. 
2010;2(7):237-43. 
25. Giovannini M, Thomas B, Erwan B, Christian P, Fabrice C, Benjamin E, et 
al. Endoscopic ultrasound elastography for evaluation of lymph nodes and 
pancreatic masses: a multicenter study. World journal of gastroenterology. 
2009;15(13):1587-93. 
26. Janssen J, Schlorer E, Greiner L. EUS elastography of the pancreas: 
feasibility and pattern description of the normal pancreas, chronic pancreatitis, 
and focal pancreatic lesions. Gastrointestinal endoscopy. 2007;65(7):971-8. 
  
72 
 
27. Hirche TO, Ignee A, Barreiros AP, Schreiber-Dietrich D, Jungblut S, Ott 
M, et al. Indications and limitations of endoscopic ultrasound elastography for 
evaluation of focal pancreatic lesions. Endoscopy. 2008;40(11):910-7. 
28. Dietrich CF, Hirche TO, Ott M, Ignee A. Real-time tissue elastography in 
the diagnosis of autoimmune pancreatitis. Endoscopy. 2009;41(8):718-20. 
29. Iglesias-Garcia J, Larino-Noia J, Dominguez-Munoz JE. [Elastography in 
the evaluation of chronic pancreatitis]. Gastroenterologia y hepatologia. 
2011;34(9):629-34. 
30. Lee TH, Cho YD, Cha SW, Cho JY, Jang JY, Jeong SW, et al. Endoscopic 
ultrasound elastography for the pancreas in Korea: a preliminary single center 
study. Clinical endoscopy. 2013;46(2):172-7. 
31. Kongkam P, Lakananurak N, Navicharern P, Chantarojanasiri T, Aye K, 
Ridtitid W, et al. Combination of EUS-FNA and elastography (strain ratio) to 
exclude malignant solid pancreatic lesions: A prospective single-blinded study. 
Journal of gastroenterology and hepatology. 2015;30(11):1683-9. 
 
